Newbury Park, CA, United States of America

Hosung Min

This inventor holds 24 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Biotechnology. Top assignee: Amgen Inc.. Active years: 2005-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hosung Min. Retrieved from https://idiyas.com/inventor/hosung-min

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 5)

% Patents Active = 50.0

CIPO Patents = 4

EPO Patents = 9 (Patent Applications = 6)

Average Co-Inventor Count = 2.7

ph-index = 13

Forward Citations = 418(Granted Patents)

Location History:

Sungnam-si, KR (2010 - 2011)
Westlake Village, CA (US) (2011 - 2013)
Sungman-si, KR (2014)
Newbury Park, CA (US) (2005 - 2015)

Company Filing History:

24 out of 2,072

Amgen Inc.

patents

Years Active: 2005-2015

Loading Chart...

Areas of Expertise:

Angiopoietin-2

Myostatin Binding Agents

Thrombopoietic Compounds

Nerve Growth Factor

Binding Agents

Peptides

Polynucleotides

Treatment Methods

Human Health

Molecular Biology

Therapeutics

Biological Activity

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9200040 - Specific binding agents of human angiopoietin-2 (2015-12-01),

2. 9139645 - Peptides and related molecules that bind to TALL-1 (2015-09-22),

3. 8920798 - Myostatin binding agents, nucleic acids encoding the same, and methods of treatment (2014-12-30),

4. 8541201 - Thrombopoietic compounds (2013-09-24),

5. 8507426 - Peptides and related molecules that bind to TALL-1 (2013-08-13),

6. 8129331 - Specific binding agents of human angiopoietin-2 (2012-03-06),

7. 8124724 - Peptides and related molecules that modulate nerve growth factor activity (2012-02-28),

8. 8071538 - Method of increasing muscle mass by administering a myostatin binding agent (2011-12-06),

9. 7981425 - Thrombopoietic compounds (2011-07-19),

10. 7928075 - Binding agents which inhibit myostatin (2011-04-19),

11. 7803923 - Polynucleotides encoding myostatin binding agents (2010-09-28),

12. 7790674 - Methods of treatment using specific binding agents of human angiopoietin-2 (2010-09-07),

13. 7737111 - Peptides and related molecules that bind to TALL-1 (2010-06-15),

14. 7723499 - Specific binding agents of human angiopoietin-2 (2010-05-25),

15. 7666839 - Methods of treatment using specific binding agents of human angiopoietin-2 (2010-02-23),

Title: Innovations by Hosung Min in the Field of Therapeutics

Introduction

Hosung Min, based in Newbury Park, CA, is an influential inventor with a remarkable portfolio of 24 patents. His work primarily focuses on developing therapeutic agents and innovative solutions in the field of biotechnology.

Latest Patents

Among his latest patents are two significant innovations. The first patent involves specific binding agents targeting human angiopoietin-2. This invention discloses peptides that bind to Ang-2, alongside methods for creating these peptides and the associated peptibodies. Additionally, it describes methods for treating conditions using these novel peptides and peptibodies.

The second patent centers on peptides and related molecules that interact with TALL-1. This invention outlines therapeutic agents that can modulate the activity of TALL-1, featuring an amino acid sequence which consists of threonyl or isoleucyl residues. The patent further describes compositions of matter that integrate a TALL-1 modulating component with a preferred vehicle, which is suggested to be an IgG Fc domain.

Career Highlights

Hosung Min has established himself as a valuable asset in the biotechnology sector, working with Amgen Inc., a prominent company in the field. His innovative approach and expertise have contributed significantly to the development of therapeutic strategies aimed at advancing healthcare solutions.

Collaborations

Throughout his career, Hosung has collaborated with notable coworkers, including Jonathan Daniel Oliner and Thomas Charles Boone. These partnerships have fostered a dynamic exchange of ideas and advancements in their shared field of research.

Conclusion

Hosung Min's contributions to the field of biotechnology through his patented inventions exemplify the spirit of innovation. His dedication to developing novel therapeutic agents continues to impact medical research and offers promising avenues for future treatment methodologies.

Profile summary based on public USPTO records.